Subcutaneous injections do not require a port like an IV, eliminating the risk for port-related complications such as infections.

Ocrevus subcutaneous injection was non-inferior to Ocrevus IV infusion as measured by Ocrevus levels in the blood of patients (area under the serum concentration time curve) from day 1 to 12 weeks ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Further, pharmacokinetic modeling predicts that convenient dosing regimens of VRDN-003 (e.g., a low volume subcutaneous injection once every 4 or 8 weeks) could achieve exposure levels of VRDN-003 ...

Basel, 14 November 2023- Roche announced today that the European Medicines Agency’ s Committee for Medicinal Products for Human Use has recommended the approval of subcutaneous Tecentriq ...

In these videos, Douglas H. Jones, MD, the medical director and CEO of Global Allergy Immune Network, discusses the latest developments in the treatment and of hereditary angioedema.

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

The FDA's approval of Alhemo (concizumab-mtci) revolutionizes hemophilia treatment, offering a simpler, subcutaneous injection for better bleed control and patient independence.

Computational models of the glucoregulatory system constitute a powerful tool for preclinical evaluation and mechanistic insight into therapeutics. However, in the case of diabetes, there is a dearth ...

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients ...